In a collaborative effort, Sage Therapeutics, Inc. and Biogen Inc. have recently disclosed the topline findings from the Phase 2 KINETIC 2 study evaluating the potential effectiveness of SAGE-324 (BIIB124) as a treatment for essential tremor (ET). This article aims to outline the key facts derived from this study and assess the impact these results may have on both pharmaceutical companies.
Summary of the Study
The Phase 2 KINETIC 2 study was designed to determine the efficacy of SAGE-324 by assessing its impact on the Essential Tremor Rating Assessment Scale (TETRAS) Perform. Regrettably, the study did not demonstrate a statistically significant dose-response relationship in the change from baseline to Day 91. This outcome casts doubt on the drug’s suitability as a treatment for ET based on the primary endpoint.
Assessing the Impact on Sage Therapeutics
For Sage Therapeutics, this outcome is undoubtedly disappointing, as the lack of a statistically significant dose-response relationship suggests that SAGE-324 may not exhibit the desired therapeutic effect on essential tremor. Consequently, further research and development efforts will be required to evaluate the drug’s potential efficacy, and it may have implications for the company’s overall pipeline and future revenue projections.
Assessing the Impact on Biogen Inc.:
As a partner in this collaboration, Biogen Inc. also experiences the setback resulting from the Phase 2 KINETIC 2 study. While the impact on Biogen’s overall operations may be relatively modest due to its diversified portfolio, this outcome underscores the inherent risks and uncertainties associated with drug development. Collaborative efforts in novel drug development often involve substantial investments, and the inconclusive study results may prompt Biogen to reconsider its future strategic partnerships or allocate resources to alternative projects.
Conclusion:
The Phase 2 KINETIC 2 study evaluating the investigational drug SAGE-324 (BIIB124) for the treatment of essential tremor has not provided statistically significant evidence regarding its efficacy. These results cast doubt on the potential of SAGE-324 as a viable treatment option for essential tremor patients. Sage Therapeutics and Biogen Inc. must now reassess their strategies and potentially redirect resources to continue the search for more effective treatment alternatives for this debilitating condition.
Comments